Your Education
Atlas of Stains
Events and Webinars
All Resources
eIFUs
Contact CDx Team
CPS
Your Education
Atlas of Stains
Events and Webinars
All Resources
eIFUs
Contact CDx Team
CPS
Triple-Negative Breast Cancer (TNBC)
Indication-specific training resources to support high-quality diagnostic assessment of TNBC specimens stained with PD-L1 IHC 22C3 pharmDx.
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Triple-Negative Breast Cancer (TNBC)
View More
PD-L1 IHC 22C3 pharmDx Interpretation Manual for Triple-Negative Breast Cancer (TNBC)
View More
PD-L1 IHC 22C3 pharmDx Quick Scoring Guide for Triple-Negative Breast Cancer (TNBC)
View More
PD-L1 Staining Immune and Tumor Cells in a Triple-Negative Breast Cancer (TNBC) case
View More
PD-L1 Staining Stromal Cells in a Triple-Negative Breast Cancer (TNBC) Case
View More
PD-L1 Staining in a Heterogenous Triple-Negative Breast Cancer (TNBC) Case
View More
The PD-1/PD-L1 Pathway
View More
The development of a CDx IHC Assay
View More
What is a CDx IHC Assay?
View More
Advanced Tutorial: Quantifying Tumor Cells in Cases with Challenging Histology
View More
Scoring Near the CPS Cutoffs: Real-World Approaches
View More
Applying The 20X Rule for Scoring CPS
View More
Efficiently Evaluating the CPS Denominator
View More
Confidence in Evaluating Combined Positive Score: How a Systematic Approach Can Simplify PD-L1 Scoring with CPS
View More
Scoring of Triple-Negative Breast Cancer (TNBC): Example Cases from PD-L1 IHC 22C3 pharmDx Atlas of Stain
View More
Assessing PD-L1 Combined Positive Score (CPS) in Various Tumor Types with Distinct Morphological Characteristics
View More
The Nuances of Tumor Types: How are Cutoffs Determined and Validated?
View More
Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape
View More
Mastering Combined Positive Score (CPS) From Principles to Real-world Applications
View More
The Pathologist and the Oncologist Working Together on PD-L1 to Improve Patient Treatment
View More
External Quality Assurance of PD-L1 Assays The NordiQC Experience
View More
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)
View More
The Value of CDx IHC Assays in the Complex Environment of PD‑L1 Testing
View More
D72740_01